Haloperidol Metabolite II
Haloperidol Metabolite II structure
|
Common Name | Haloperidol Metabolite II | ||
|---|---|---|---|---|
| CAS Number | 34104-67-1 | Molecular Weight | 377.88000 | |
| Density | 1.247g/cm3 | Boiling Point | 531.2ºC at 760 mmHg | |
| Molecular Formula | C21H25ClFNO2 | Melting Point | 125-127°C | |
| MSDS | USA | Flash Point | 275.1ºC | |
|
Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.
Psychopharmacology 205 , 21-33, (2009) We evaluated the effects of haloperidol and its metabolites on capsaicin-induced mechanical hypersensitivity (allodynia) and on nociceptive pain induced by punctate mechanical stimuli in mice.Subcutaneous administration of haloperidol or its metabolites I or ... |
|
|
Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.
Anal. Bioanal. Chem 386(3) , 719-24, (2006) A simultaneous method for the determination of haloperidol (HP) and its metabolite, reduced haloperidol (RHP), in human serum was developed by means of high-performance liquid chromatography (HPLC) with fluorescence detection. Suzuki coupling reaction with a ... |
|
|
Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Eur. Neuropsychopharmacol. 4(2) , 119-26, (1994) Plasma haloperidol (HL) and reduced haloperidol (RH) levels were measured in 60 schizophrenic patients treated with high to very high HL doses of 40-200 mg/day. Plasma samples were obtained at steady-state conditions and 10-12 h after the evening dose and pri... |
|
|
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Int. Clin. Psychopharmacol. 14(4) , 219-28, (1999) The aim of this study was to investigate the effect of reduced haloperidol, the main metabolite of the antipsychotic drug haloperidol, on psychopathology improvement and extrapyramidal adverse effects in acute schizophrenia. The steady-state pharmacokinetics ... |
|
|
Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
Prog. Neuropsychopharmacol. Biol. Psychiatry 18(2) , 347-53, (1994) 1. The authors attempted to correlate plasma concentrations in H/rH and clinical efficacy from 8 schizophrenic patients (DSM IIIR) on H. 2. No significant correlations were found between H, rH plasma levels and positive and negative subscale for each patient.... |
|
|
Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.
Ther. Drug Monit. 22(3) , 245-9, (2000) The effect of a genetic polymorphism of inducibility of cytochrome P450 (CYP) 1A2 on the steady state plasma concentrations (Css) of haloperidol and reduced haloperidol was studied to clarify if these Css are dependent on the CYP1A2 activity. The subjects wer... |
|
|
Co-administration of sertraline and haloperidol.
Psychiatry Clin. Neurosci. 52 Suppl , S193-8, (1998) Along with recent increased interest in the selective serotonin reuptake inhibitors, a number of studies has been undertaken to observe interactions with different drugs. When selective serotonin reuptake inhibitor was administered together with antipsychotic... |
|
|
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.
Ther. Drug Monit. 25(2) , 192-6, (2003) The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients r... |
|
|
Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
Neuropsychobiology 36(1) , 32-6, (1997) Thirty six schizophrenic patients were randomly assigned to placebo or haloperidol treatment for 6 weeks. Blood samples to measure plasma alpha-one acid glycoprotein (AAG), haloperidol and reduced haloperidol concentrations were obtained at baseline and weeks... |
|
|
Effect of a pyridinium metabolite derived from haloperidol on the activities of striatal tyrosine hydroxylase in freely moving rats.
Neurosci. Lett. 214(2-3) , 183-6, (1996) The effects of a pyridinium metabolite (HPP+) derived from haloperidol (HP) on in vivo tyrosine hydroxylation was evaluated in freely moving rats. As an index of the in vivo activity of tyrosine hydroxylase (TH), the rat striatum was perfused with NSD-1015, a... |